You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that that it submitted an application for marketing approval in...
TOKYO – November 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data in acute myeloid leukemia (AML) research, including...
Tokyo, November 28, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have...
Tokyo and San Francisco, October 31, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...
Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and...
Read more about Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family)
Tokyo, October 30, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a screening collaboration agreement with Medicines...
Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...
Tokyo, October 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a new collaborative research agreement with TB...
Follow us
